H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Aveo Pharmaceuticals to $9 saying the company announced positive topline results from the Phase 3 TIVO-3 study investigating the use of tivozanib for the treatment of refractory renal cell carcinoma. The analyst views the results as “very promising” and believes tivozanib still has “ample opportunity” to show a superior overall survival benefit. He believes the drug is on track for approval in 2020 and keeps a Buy rating on Aveo Pharmaceuticals.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.